JP2004224797A - アルツハイマー病を治療するためのステロイドサポゲニンとその誘導体 - Google Patents
アルツハイマー病を治療するためのステロイドサポゲニンとその誘導体 Download PDFInfo
- Publication number
- JP2004224797A JP2004224797A JP2004073546A JP2004073546A JP2004224797A JP 2004224797 A JP2004224797 A JP 2004224797A JP 2004073546 A JP2004073546 A JP 2004073546A JP 2004073546 A JP2004073546 A JP 2004073546A JP 2004224797 A JP2004224797 A JP 2004224797A
- Authority
- JP
- Japan
- Prior art keywords
- receptor
- receptors
- compounds
- sdat
- effects
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8964—Anemarrhena
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8965—Asparagus, e.g. garden asparagus or asparagus fern
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/90—Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9406—Neurotransmitters
- G01N33/944—Acetylcholine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Psychiatry (AREA)
- Analytical Chemistry (AREA)
Abstract
【解決手段】 本発明は、認識機能不全及び類似の状態の治療において、多くのサポニンとサポゲニン、特にステロイド構造のそれらの使用を開示する。治療の方法、及び薬学組成物もまた開示する。
【選択図】 なし
Description
AD/SDATの中のリサーチは、伝統的でかつ通常の医薬リサーチ法と規律によって実施されている。通常の医薬において、AD/SDATの治療のための幾つかのアプローチがある。大脳皮質において記憶を促進する生化学プロセスは(少なくとも部分的に)、コリン作用的に−仲介されることが知られる。当業者であれば、「コリン作用的に仲介された」メカニズムが、レセプター上で作用するアセチルコリンに直接起因し得ること、及び直接影響を及ぼすことを知るであろう。その他、臨床的に有用な作用は、シナプス前部の神経末端からのアセチルコリンの放出の変調又はアセチルコリンを破壊する酵素の阻害によってもまた、生じるであろう。これらの変調作用因子は、メディエイタが非-コリン作用性である場合に、ニューロンを通して効力を発揮し得る;これらは間接的な作用として関与する。治療における幾つかの試みが、中脳核のような脳の他のエリアにおけるメディエイタである、5−ヒドロキシトリプタミンのような他のメディエイタの役割に集中している。しかしながら、最初の伝達物質がアセチルコリンである場合、これらのエリアからの繊維が大脳皮質の内部に向かって出されることから、試みは、適当な治療薬のサーチにおけるこのメディエイタの管理に集中している。
プロゲステロン
グルココルチコイド
テストステロン
1.チャイニーズハムスター卵巣(CHO)細胞をムスカリン性レセプターをコードしているDNAフラグメントとトランスフェクションした。大部分の実験に使用した細胞系は、m2レセプターを発現している細胞系とした。
2.神経由来の培養した細胞系におけるムスカリン性レセプター発現の効果を調査した。
3.培養心筋細胞は、Sprague Dawleyラットから得た。該心筋細胞は、ムスカリンレセプター、典型的にm2を発現する。これらのレセプターのレベルが延長された培養で低下し、予防における重要な化合物の効果がレセプター数において低下することを調査した。
これらの実験の方法と結果を順次ここに記載する。
m2レセプターをDNAにトランスフェクションしたCHO細胞上のm2レセプターの発現における各種化合物の効果を調べた。レセプター数は、滴定したQNB結合を用い、且つ非特異的結合を差し引きすることでアッセイした。化合物は、DMSOに溶かし、またDMSOをコントロールとして用いた。化合物は、最終濃度の範囲で試験した。化合物はまた、エストロゲン性レセプター介在メカニズムを識別する試みのためにタモキシフェンの存在と不在においてもまた試験した。その結果を以下の表3中に要約した。
他のインビトロでのアッセイが、活性及び不活性化合物との間を識別するために用いられる。特に、SKN−SN及びSH−SY5Y細胞、同じくファエクロモアシトーマ(phaechromoacytoma)細胞系を含む各種の神経芽細胞系を、β−アミロイドフラグメント又は血清剥離の存在中、インビトロで培養している。培養細胞の保護における化合物の有効性を実証するための多くの技術を調査した。これらの技術は、トリバンブルー排除、化学ルミネッセンス及び乳酸脱水素酵素の放出を含む。最も興味あることが、放射性標識リガンド結合技術を用いて測定した、細胞、特にPC12細胞と、β−アミロイドとの、ムスカリン性レセプターの数を減じたインキュベーションで観測された。レセプター数におけるこの減少は、活性化合物によって改善されることが見出された。
心筋細胞は、標準技術を用いて新生児Sprague Dawleyラットの心室筋肉から単離した。細胞はインビトロで培養し、各種時間点で採取した細胞の均質化後の細胞表面膜フラグメントを発現したムスカリン性レセプターの数は、滴定したQNBの特異的結合を用いて評価した。最初の実験は、発現したレセプターの数が培養の10日後に低下する傾向であったことを示した。その実験は、従って、レセプター数におけるこの減少を抑制することにおいての各種化合物の効果を調べるために表した。
2.二次的に増加したレセプター数、α−セクレターゼ活性の重大な増加に伴うPKCの刺激の増加は以下のことに帰結する:
2.1 β−アミロイドの減じられた生産及び結果として起こるプラーク形成とニューロン損失の減少;
2.2 APPsαの増加及び結果として起こる短期及び長期記憶の改善によって証明されるような大脳機能の改善。
20月齢の純系オスSDラットを、2つの群に無作為に分割した。一方の群には、ラット当たり1日当たり平均3mgのサルササポゲニンを毎日餌と混合して与えた。コントロール群は、正常な餌と水を与えた。4ヶ月後、それらの脳をハイブリダイゼーション技術実験で使用するとともに、4乃至6月齢のラットを若年コントロール群として用いた。それぞれの群の他の給餌列は、完全に同一であった。
Claims (5)
- サルササポゲニンを有効成分として含むパーキンソン病の治療剤。
- サルササポゲニン及びスミラゲニンの一つ以上を有効成分として含む、レウィ体痴呆、体位性低血圧症、自閉症、慢性疲労症候群、重症筋無力症、ランバート‐イートン症候群、湾岸戦争症候群、及び有機燐化合物への職業上の曝露から選択される疾患の治療剤。
- スミラゲニン、アンズロゲニンD、及びアストラガロシドから選択される少なくとも一つの更なる有効成分を含む請求項2に記載の治療剤。
- アンズロゲニンD及びアストラガロシドから選択される少なくとも一つの更なる有効成分を含む請求項3に記載の治療剤。
- 前記有効成分が、サルトリイバラ(Smilax)、アスパラガス(Asparagus)、アネマルヘナ(Anemarrhena)、イトラン(Yucca)、又はリュウゼツラン(Agave)属の植物の抽出物である請求項1から4のいずれか一項に記載の治療剤。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9806513.9A GB9806513D0 (en) | 1998-03-26 | 1998-03-26 | Membrane-bound receptors |
GBGB9905275.5A GB9905275D0 (en) | 1999-03-08 | 1999-03-08 | Treatment of conditions associated with membrane-bound receptors and their function |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000537555A Division JP3768100B2 (ja) | 1998-03-26 | 1999-03-26 | アルツハイマー病を治療するためのステロイドサポゲニンとその誘導体 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2004224797A true JP2004224797A (ja) | 2004-08-12 |
Family
ID=26313369
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000537555A Expired - Fee Related JP3768100B2 (ja) | 1998-03-26 | 1999-03-26 | アルツハイマー病を治療するためのステロイドサポゲニンとその誘導体 |
JP2000537532A Pending JP2003524581A (ja) | 1998-03-26 | 1999-03-26 | アルツハイマー病の治療のためのスミラゲニン及びアンズロゲニン−d |
JP2004073546A Pending JP2004224797A (ja) | 1998-03-26 | 2004-03-15 | アルツハイマー病を治療するためのステロイドサポゲニンとその誘導体 |
JP2004073541A Pending JP2004217666A (ja) | 1998-03-26 | 2004-03-15 | アルツハイマー病を治療するためのステロイドサポゲニンとその誘導体 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000537555A Expired - Fee Related JP3768100B2 (ja) | 1998-03-26 | 1999-03-26 | アルツハイマー病を治療するためのステロイドサポゲニンとその誘導体 |
JP2000537532A Pending JP2003524581A (ja) | 1998-03-26 | 1999-03-26 | アルツハイマー病の治療のためのスミラゲニン及びアンズロゲニン−d |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004073541A Pending JP2004217666A (ja) | 1998-03-26 | 2004-03-15 | アルツハイマー病を治療するためのステロイドサポゲニンとその誘導体 |
Country Status (28)
Country | Link |
---|---|
US (2) | US6812213B2 (ja) |
EP (3) | EP1066033B1 (ja) |
JP (4) | JP3768100B2 (ja) |
KR (6) | KR100632052B1 (ja) |
CN (3) | CN1198622C (ja) |
AT (3) | ATE507834T1 (ja) |
AU (2) | AU748138B2 (ja) |
BR (2) | BR9909109A (ja) |
CA (2) | CA2325634A1 (ja) |
CY (1) | CY1105653T1 (ja) |
DE (3) | DE69929177T2 (ja) |
DK (2) | DK1719512T3 (ja) |
ES (2) | ES2257042T3 (ja) |
GB (1) | GB2335599B (ja) |
HK (3) | HK1033742A1 (ja) |
HR (2) | HRP20000638A2 (ja) |
HU (2) | HUP0101693A3 (ja) |
ID (2) | ID26781A (ja) |
IL (4) | IL138663A0 (ja) |
IS (2) | IS5638A (ja) |
MX (1) | MXPA00009437A (ja) |
NO (4) | NO20004803L (ja) |
NZ (1) | NZ507355A (ja) |
PL (3) | PL207723B1 (ja) |
PT (1) | PT1066042E (ja) |
RU (1) | RU2297228C2 (ja) |
TR (2) | TR200002774T2 (ja) |
WO (2) | WO1999048507A2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009256243A (ja) * | 2008-04-17 | 2009-11-05 | Noevir Co Ltd | 保湿剤、抗老化剤、抗酸化剤、皮膚外用剤及び機能性経口組成物 |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6277978B1 (en) | 1995-12-22 | 2001-08-21 | University Of Utah Research Foundation | KVLQT1—a long QT syndrome gene |
AU781810B2 (en) * | 1998-03-26 | 2005-06-16 | Phytopharm Plc. | Steroidal sapogenins and their derivatives for treating Alzheimer's disease |
HUP0101693A3 (en) * | 1998-03-26 | 2002-08-28 | Phytopharm Plc Godmanchester | Use of steroidal sapogenins and their derivatives for producing pharmaceutical compositions for the treatment of alzheimeirs disease |
US20030118673A1 (en) * | 1998-03-26 | 2003-06-26 | Zongqin Xia | Smilagenin and anzurogenin-D for the treatment of alzheimer's disease |
GB9923076D0 (en) * | 1999-09-29 | 1999-12-01 | Phytopharm Plc | Sapogenin derivatives and their use |
GB2347676A (en) * | 1999-03-08 | 2000-09-13 | Phytopharm Plc | Screening method |
US20010024664A1 (en) * | 1999-03-19 | 2001-09-27 | Obukowicz Mark G. | Selective COX-2 inhibition from edible plant extracts |
GB9923078D0 (en) * | 1999-09-29 | 1999-12-01 | Phytopharm Plc | Sapogenin derivatives and their use |
GB9923077D0 (en) * | 1999-09-29 | 1999-12-01 | Phytopharm Plc | Sapogenin derivatives and their use |
GB0000228D0 (en) * | 2000-01-06 | 2000-03-01 | Phytopharm Plc | Fluoro substituted sapogenins and their use |
GB0107822D0 (en) * | 2001-03-28 | 2001-05-23 | Phytopharm Plc | Sapogenin derivatives their synthesis and use methods based upon their use |
US20050130948A1 (en) * | 2002-03-27 | 2005-06-16 | Daryl Rees | Therapeutic methods and uses of sapogenins and their derivatives |
NZ547897A (en) * | 2002-03-27 | 2008-02-29 | Phytopharm Plc | Therapeutic methods and uses of sapogenins and their derivatives |
PT1490071E (pt) * | 2002-03-27 | 2009-05-25 | Phytopharm Plc | Métodos terapêuticos e utilizações de sapogeninas e seus derivados |
AU2003229877B8 (en) * | 2002-03-27 | 2008-06-12 | Phytopharm Plc | Theraputic methods and uses of sapogenins and their derivatives |
CN102727501A (zh) * | 2002-03-27 | 2012-10-17 | 菲特法姆股份有限公司 | 皂角苷配基及其衍生物的用途 |
ATE459636T1 (de) * | 2002-10-28 | 2010-03-15 | Phytopharm Plc | Stereospezifische reduktion von sapogen-3-onen |
GB0329667D0 (en) * | 2003-12-22 | 2004-01-28 | King S College London | Core 2 GlcNAc-T inhibitor |
GB0513881D0 (en) * | 2005-07-06 | 2005-08-10 | Btg Int Ltd | Core 2 GLCNAC-T Inhibitors III |
US20080182801A1 (en) * | 2003-12-22 | 2008-07-31 | Btg International Limited | Core 2 glcnac-t inhibitors |
GB0409567D0 (en) * | 2004-04-28 | 2004-06-02 | Phytopharm Plc | Chemical compounds |
CA2584333A1 (en) * | 2004-10-14 | 2006-04-27 | Georgetown University | Neuroprotective spirostenol pharmaceutical compositions |
GB0424528D0 (en) | 2004-11-05 | 2004-12-08 | Phytopharm Plc | Chemical compounds |
GB0512726D0 (en) * | 2005-06-22 | 2005-07-27 | Btg Int Ltd | Multiple sclerosis therapy and diagnosis |
GB0513883D0 (en) * | 2005-07-06 | 2005-08-10 | Btg Int Ltd | Diagnosis of Atherosclerosis |
GB0513888D0 (en) * | 2005-07-06 | 2005-08-10 | Btg Int Ltd | Core 2 GLCNAC-T Inhibitors II |
KR100779179B1 (ko) * | 2006-05-19 | 2007-11-28 | 충북대학교 산학협력단 | 토복령의 메탄올 추출물을 함유하는 뇌신경 보호 또는퇴행성뇌질환 예방 또는 치료제 |
US8217165B2 (en) | 2008-06-17 | 2012-07-10 | Pawan Kumar Goel | Process for the extraction of furostanolic saponins from fenugreek seeds |
KR101027384B1 (ko) * | 2009-06-29 | 2011-04-11 | 에이디엠이십일 주식회사 | 플랫와이퍼블레이드와 와이퍼아암의 연결장치 |
KR20110115589A (ko) | 2009-01-24 | 2011-10-21 | 파이토팜 피엘씨 | 신경영양인자가 매개된 장애의 치료 |
EP2595621A1 (en) | 2010-07-20 | 2013-05-29 | Phytopharm PLC | Treatment of l-dopa, dopamine agonist and/or dopamine enhancer induced disorders |
TWI422378B (zh) * | 2010-11-18 | 2014-01-11 | Univ Chung Shan Medical | 使用薯蕷皂素來改善與停經期症候群有關聯的認知缺陷 |
CN102389438A (zh) * | 2011-06-30 | 2012-03-28 | 北京师范大学 | 黄芪甲苷的应用 |
WO2014112145A1 (ja) * | 2013-01-21 | 2014-07-24 | レジリオ株式会社 | アルツハイマー病等を含む神経疾患の1,25d3-marrsが関与する治療薬及び治療法 |
KR101777920B1 (ko) * | 2015-07-27 | 2017-09-14 | 재단법인 지능형 바이오 시스템 설계 및 합성 연구단 | 진세노사이드 f1을 포함하는 아밀로이드 플라크 제거용 조성물 |
CN105168785A (zh) * | 2015-10-08 | 2015-12-23 | 湖北民族学院 | 一种治疗阿尔茨海默病的中药制剂及制备方法 |
EP3572085A1 (en) | 2018-05-25 | 2019-11-27 | Neuro-Sys | Synergestic combination composition comprising a steroidal saponin, a first polyphenolic compound and optionnaly a second polyphenolic compound |
CN108514603B (zh) * | 2018-06-28 | 2021-12-28 | 佳木斯大学 | 一种治疗强直型帕金森病的中药组合物及其制备方法 |
KR102028730B1 (ko) | 2019-05-22 | 2019-10-04 | (주)클래시스 | 집속초음파 기술을 이용한 지모 추출물의 제조방법 및 이로부터 수득된 지모 추출물 |
CN110859849A (zh) * | 2019-12-11 | 2020-03-06 | 大连医科大学 | 薯蓣皂苷在制备帕金森病保护药物中的应用 |
US11788574B2 (en) | 2021-08-13 | 2023-10-17 | Rimgard Sweden AB | Anti-theft locking bolt assembly |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE794362A (fr) * | 1972-01-22 | 1973-07-23 | Merck Patent Gmbh | Sulfates hydrosolubles de sterine |
US3929769A (en) * | 1972-05-19 | 1975-12-30 | Ciba Geigy Corp | Process for the manufacture of steroid epoxides |
CA985172A (en) | 1972-10-06 | 1976-03-09 | Dushan M. Dvornik | Compositions and methods for reducing blood cholesterol |
DE2416978A1 (de) * | 1974-04-08 | 1975-10-09 | Degussa | Arzneimittel mit dem hauptsapogenin der helleborus-arten als wirkstoff |
LU81256A1 (fr) | 1979-05-15 | 1980-12-16 | Oreal | Composition cosmetique capillaire notamment pour le lavage et/ou le demelage des cheveux,a base d'un extrait de plantes contenant des saponosides |
JPS5855500A (ja) * | 1981-09-25 | 1983-04-01 | Tokiwa Yakuhin Kogyo Kk | 16−デヒドロプレグネノロンの製造法 |
US4602005A (en) * | 1982-05-17 | 1986-07-22 | Medical Research Foundation Of Oregon | Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis |
US4602003A (en) * | 1982-05-17 | 1986-07-22 | Medical Research Foundation Of Oregon | Synthetic compounds to inhibit intestinal absorption of cholesterol in the treatment of hypercholesterolemia |
US4562250A (en) * | 1982-09-13 | 1985-12-31 | Regents Of The University Of Minnesota | Steroidal glycosides produced by Yucca tissue culture |
US4546097A (en) * | 1983-11-04 | 1985-10-08 | The United States Of America As Represented By The Department Of Health And Human Services | Saponin-based polyether polyols, pharmaceutical compositions and a method of using same |
US4680289A (en) | 1985-06-05 | 1987-07-14 | Progenics, Inc. | Treatment of obesity and diabetes using sapogenins |
US5017562A (en) | 1987-02-11 | 1991-05-21 | Regents Of The University Of Minnesota | Crystalline saponin-containing complex |
DE3838716A1 (de) * | 1988-11-15 | 1990-05-17 | Kanoldt Arzneimittel Gmbh | Arzneimittelzubereitung aus esterderivaten des hecogenins und dessen verwendung zur behandlung von benigner prostatahyperplasie |
BR9105952A (pt) * | 1990-01-18 | 1992-11-17 | Cura Nominees Pty Ltd | Metodo para identificar composto e para controlar autofagia celular,aglutinacao ou imobilizacao celulares de celulas moveis,metodo para tratamento de cancer,contracepcao,termino de gravidez,remocao de organismos patogenicos e de desenvolvimento celular anormal,metodo de induzir autofagia celular,aglutinacao ou imobilizacao celulares em um corpo animal,metodo de marcar e identificar celula-alvo,composto e composicao contendo pelo menos um composto para controlar autofagia celular,aglutinacao ou imobilizacao celuares de celulas moveis |
US5252729A (en) * | 1991-10-23 | 1993-10-12 | Schering Corporation | Extraction of compounds from plant materials using supercritical fluids |
US5244887A (en) * | 1992-02-14 | 1993-09-14 | Straub Carl D | Stanols to reduce cholesterol absorption from foods and methods of preparation and use thereof |
CZ331094A3 (en) * | 1992-06-26 | 1995-09-13 | Pfizer | Steroidal glycosides and their use for treating hypercholesterolemia and atherosclerosis |
DE4303214A1 (de) * | 1993-02-04 | 1994-08-11 | Wolfgang Marks | Behandlung von Erkrankungen viraler, viroidaler oder onkogener Genese durch Steroid-Saponine oder deren Aglykone |
WO1994018994A1 (en) * | 1993-02-23 | 1994-09-01 | Pharmakon Usa, Inc. | Therapeutic herbal composition |
CN1092992A (zh) * | 1993-03-29 | 1994-10-05 | 中国科学院沈阳应用生态研究所 | 提高脑功能的药物及其制备方法 |
CN1052636C (zh) * | 1993-03-29 | 2000-05-24 | 中国科学院沈阳应用生态研究所 | 文冠果子的醇提取物在制备治疗智力低下的药物中的应用 |
CA2161239A1 (en) * | 1993-04-28 | 1994-11-10 | Douglas J.M. Allen | Spirostanyl glycosidal crystalline monohydrate |
CN1033754C (zh) * | 1993-05-31 | 1997-01-08 | 上海第二医科大学 | 知母皂甙元作为制备β肾上腺素和M胆碱受体双向调节药的用途及其制法 |
US5589182A (en) * | 1993-12-06 | 1996-12-31 | Tashiro; Renki | Compositions and method of treating cardio-, cerebro-vascular and alzheimer's diseases and depression |
JPH09500906A (ja) * | 1993-12-28 | 1997-01-28 | ファイザー・インク. | 血中コレステロール低下薬 |
EP0737203A1 (en) * | 1993-12-28 | 1996-10-16 | Pfizer Inc. | Steroidal glycosides |
US5840740A (en) * | 1995-06-07 | 1998-11-24 | Magainin Pharmaceuticals Inc. | Aminosterol compounds and a method of treating infection using the aminosterol compounds |
US5856535A (en) * | 1994-08-18 | 1999-01-05 | Magainin Pharmaceuticals, Inc. | Aminosterol ester compounds |
PL318937A1 (en) * | 1994-08-30 | 1997-07-21 | Pfizer | Spirostanyloglycoside crystals |
MX9702175A (es) * | 1994-09-20 | 1997-06-28 | Pfizer | Combinacion de un inhibidor de absorcion de colesterol y un inhibidor de sintesis de colesterol. |
US6150336A (en) * | 1995-05-29 | 2000-11-21 | Pfizer Inc. | Steroidal glycosides |
US5840936A (en) * | 1995-06-07 | 1998-11-24 | Magainin Pharmaceuticals Inc. | Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE) |
US5763430A (en) * | 1995-06-07 | 1998-06-09 | Magainin Pharmaceuticals Inc. | Method of treating a viral infection by administering a steroid compound |
US5792635A (en) * | 1995-06-07 | 1998-08-11 | Magainin Pharmaceuticals, Inc. | Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine |
US5847172A (en) * | 1995-06-07 | 1998-12-08 | Magainin Pharmaceuticals Inc. | Certain aminosterol compounds and pharmaceutical compositions including these compounds |
US6143738A (en) * | 1995-06-07 | 2000-11-07 | Magainin Pharmaceuticals, Inc. | Therapeutic uses for an aminosterol compound |
US5795885A (en) * | 1995-06-07 | 1998-08-18 | Magainin Pharmaceuticals Inc. | Method of inhibiting profileration of cells by administering an aminosterol compound |
US5804239A (en) | 1996-07-26 | 1998-09-08 | Nouveau Technologies, Inc. | Method and composition for food flavoring |
EP1019044B1 (en) * | 1997-05-15 | 2007-04-11 | University of Washington | Composition and methods for treating alzheimer's disease and other amyloidoses |
CN1268027A (zh) * | 1997-08-28 | 2000-09-27 | Cv技术公司 | 草本提取物的化学和药理学标准化方法 |
CN1131237C (zh) | 1997-09-26 | 2003-12-17 | 中国人民解放军军事医学科学院放射医学研究所 | 甾体皂甙防治老年性痴呆的用途及新的甾体皂甙 |
JP3873097B2 (ja) * | 1997-11-06 | 2007-01-24 | 独立行政法人理化学研究所 | 抗肥満剤及び脂質代謝改善剤 |
GB9905275D0 (en) * | 1999-03-08 | 1999-04-28 | Phytopharm Ltd | Treatment of conditions associated with membrane-bound receptors and their function |
HUP0101693A3 (en) * | 1998-03-26 | 2002-08-28 | Phytopharm Plc Godmanchester | Use of steroidal sapogenins and their derivatives for producing pharmaceutical compositions for the treatment of alzheimeirs disease |
US6544566B1 (en) * | 1999-04-23 | 2003-04-08 | Protein Technologies International, Inc. | Composition containing plant sterol, soy protein and isoflavone for reducing LDL cholesterol |
-
1999
- 1999-03-26 HU HU0101693A patent/HUP0101693A3/hu unknown
- 1999-03-26 KR KR1020007010677A patent/KR100632052B1/ko not_active IP Right Cessation
- 1999-03-26 IL IL13866399A patent/IL138663A0/xx not_active IP Right Cessation
- 1999-03-26 PL PL380866A patent/PL207723B1/pl unknown
- 1999-03-26 DK DK06017380.4T patent/DK1719512T3/da active
- 1999-03-26 KR KR1020097000581A patent/KR20090009997A/ko not_active Application Discontinuation
- 1999-03-26 BR BR9909109-7A patent/BR9909109A/pt not_active Application Discontinuation
- 1999-03-26 EP EP99913462A patent/EP1066033B1/en not_active Expired - Lifetime
- 1999-03-26 EP EP06017380A patent/EP1719512B1/en not_active Expired - Lifetime
- 1999-03-26 PL PL99343423A patent/PL195897B1/pl not_active IP Right Cessation
- 1999-03-26 GB GB9907100A patent/GB2335599B/en not_active Expired - Fee Related
- 1999-03-26 ES ES99913462T patent/ES2257042T3/es not_active Expired - Lifetime
- 1999-03-26 KR KR1020097000085A patent/KR101092050B1/ko not_active IP Right Cessation
- 1999-03-26 TR TR2000/02774T patent/TR200002774T2/xx unknown
- 1999-03-26 DE DE69929177T patent/DE69929177T2/de not_active Expired - Lifetime
- 1999-03-26 CA CA002325634A patent/CA2325634A1/en not_active Abandoned
- 1999-03-26 TR TR2000/02773T patent/TR200002773T2/xx unknown
- 1999-03-26 AT AT06017380T patent/ATE507834T1/de not_active IP Right Cessation
- 1999-03-26 WO PCT/GB1999/000951 patent/WO1999048507A2/en active IP Right Grant
- 1999-03-26 NZ NZ507355A patent/NZ507355A/xx unknown
- 1999-03-26 ID IDW20002147A patent/ID26781A/id unknown
- 1999-03-26 KR KR1020007010698A patent/KR100713311B1/ko not_active IP Right Cessation
- 1999-03-26 EP EP99913453A patent/EP1066042B1/en not_active Expired - Lifetime
- 1999-03-26 HU HU0103654A patent/HUP0103654A2/hu unknown
- 1999-03-26 MX MXPA00009437A patent/MXPA00009437A/es active IP Right Grant
- 1999-03-26 DE DE69943415T patent/DE69943415D1/de not_active Expired - Lifetime
- 1999-03-26 AU AU31574/99A patent/AU748138B2/en not_active Ceased
- 1999-03-26 CN CNB998061581A patent/CN1198622C/zh not_active Expired - Fee Related
- 1999-03-26 JP JP2000537555A patent/JP3768100B2/ja not_active Expired - Fee Related
- 1999-03-26 ES ES99913453T patent/ES2272060T3/es not_active Expired - Lifetime
- 1999-03-26 AT AT99913453T patent/ATE337788T1/de active
- 1999-03-26 IL IL13866499A patent/IL138664A0/xx unknown
- 1999-03-26 AT AT99913462T patent/ATE314057T1/de active
- 1999-03-26 WO PCT/GB1999/000960 patent/WO1999048482A2/en not_active Application Discontinuation
- 1999-03-26 KR KR1020067027786A patent/KR20070007214A/ko not_active Application Discontinuation
- 1999-03-26 PL PL99343508A patent/PL343508A1/xx unknown
- 1999-03-26 KR KR1020077027370A patent/KR20070117001A/ko not_active Application Discontinuation
- 1999-03-26 JP JP2000537532A patent/JP2003524581A/ja active Pending
- 1999-03-26 CA CA002325633A patent/CA2325633C/en not_active Expired - Fee Related
- 1999-03-26 AU AU31581/99A patent/AU3158199A/en not_active Abandoned
- 1999-03-26 CN CNB998060429A patent/CN1209112C/zh not_active Expired - Fee Related
- 1999-03-26 PT PT99913453T patent/PT1066042E/pt unknown
- 1999-03-26 CN CNB2005100529656A patent/CN100377714C/zh not_active Expired - Fee Related
- 1999-03-26 DK DK99913453T patent/DK1066042T3/da active
- 1999-03-26 DE DE69933016T patent/DE69933016T2/de not_active Expired - Lifetime
- 1999-03-26 BR BR9909110-0A patent/BR9909110A/pt not_active Application Discontinuation
- 1999-03-26 ID IDW20002146A patent/ID26989A/id unknown
-
2000
- 2000-09-24 IL IL138663A patent/IL138663A/en unknown
- 2000-09-25 IS IS5638A patent/IS5638A/is unknown
- 2000-09-25 IS IS5637A patent/IS5637A/is unknown
- 2000-09-26 HR HR20000638A patent/HRP20000638A2/hr not_active Application Discontinuation
- 2000-09-26 NO NO20004803A patent/NO20004803L/no not_active Application Discontinuation
- 2000-09-26 NO NO20004804A patent/NO20004804L/no not_active Application Discontinuation
- 2000-09-26 HR HR20000637A patent/HRP20000637A2/hr not_active Application Discontinuation
-
2001
- 2001-06-20 HK HK01104289A patent/HK1033742A1/xx not_active IP Right Cessation
- 2001-06-22 HK HK01104373A patent/HK1033903A1/xx not_active IP Right Cessation
-
2002
- 2002-02-15 US US10/077,493 patent/US6812213B2/en not_active Expired - Fee Related
-
2004
- 2004-03-15 JP JP2004073546A patent/JP2004224797A/ja active Pending
- 2004-03-15 JP JP2004073541A patent/JP2004217666A/ja active Pending
- 2004-07-17 US US10/894,425 patent/US20060182817A1/en not_active Abandoned
- 2004-07-29 RU RU2004123463/15A patent/RU2297228C2/ru not_active IP Right Cessation
-
2006
- 2006-04-11 IL IL174991A patent/IL174991A0/en unknown
- 2006-10-10 CY CY20061101448T patent/CY1105653T1/el unknown
- 2006-11-22 HK HK06112803.6A patent/HK1091417A1/xx not_active IP Right Cessation
-
2008
- 2008-09-19 NO NO20083993A patent/NO20083993L/no not_active Application Discontinuation
- 2008-12-16 NO NO20085251A patent/NO20085251L/no unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009256243A (ja) * | 2008-04-17 | 2009-11-05 | Noevir Co Ltd | 保湿剤、抗老化剤、抗酸化剤、皮膚外用剤及び機能性経口組成物 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3768100B2 (ja) | アルツハイマー病を治療するためのステロイドサポゲニンとその誘導体 | |
US6258386B1 (en) | Smilagenin and its use | |
US7368137B2 (en) | Smilagenin and its use | |
RU2242978C2 (ru) | Стероидные сапогенины и их производные для лечения болезни альцгеймера | |
AU781810B2 (en) | Steroidal sapogenins and their derivatives for treating Alzheimer's disease | |
MXPA00009441A (en) | Membrane-bound receptors and their function;cognitive disfunction;treatments therefor;and compositions for use in such treatments | |
CZ20003541A3 (cs) | Steroidní sapogeniny a jejich deriváty pro léčbu Alzheimerovy nemoci |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040809 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080219 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080514 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080519 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080619 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080624 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080714 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080930 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20090203 |